PPAR激动剂改善原发性胆汁性胆管炎瘙痒与生活质量的Meta分析
该系统评价与Meta分析纳入5项随机安慰剂对照试验(n=660),评估贝特类、elafibranor和seladelpar对PBC瘙痒及健康相关生活质量的影响。PPAR激动剂在3、6、12个月显著降低瘙痒NRS评分,但PBC-40总分反映的总体生活质量改善未能证实。
要点
- PPAR激动剂可显著降低PBC患者中重度瘙痒的NRS评分。
- 贝特类和seladelpar在至少两个时间点达统计学显著。
- 总体健康相关生活质量改善证据不足,确定性较低。
核心结论
- PPAR激动剂(尤其贝特类和seladelpar)可减轻PBC患者中重度瘙痒严重程度,并持续改善瘙痒特异性结局。
- 对总体健康相关生活质量的效应仍不确定。
研究设计与样本
- 系统评价与Meta分析,检索截至2025年12月的PPAR激动剂治疗PBC的随机安慰剂对照试验。
- 纳入5项RCT,共660例(PPAR激动剂390例,安慰剂270例),评估贝特类、elafibranor和seladelpar。
主要发现
- PPAR激动剂在3个月显著降低NRS评分(MD -1.39;95%CI -2.49至-0.29)。
- 6个月NRS评分显著降低(MD -1.17;95%CI -1.96至-0.38)。
- 12个月NRS评分显著降低(MD -1.73;95%CI -3.00至-0.46)。
- 贝特类和seladelpar在至少两个时间点的个体药物分析中达统计学显著。
- PBC-40瘙痒域和5D瘙痒评分有改善,但PBC-40总分未显示总体生活质量改善,确定性较低。
关键数值与推荐
- 瘙痒强度分析在可得数据时限于基线中重度症状者(NRS≥4)。
- 主要结局为NRS评分和PBC-40总分,采用随机效应模型计算合并均数差(MD)及95%CI。
临床怎么用
- 对于UDCA应答不足且伴中重度瘙痒的PBC患者,PPAR激动剂可作为改善瘙痒症状的二线选择。
- 应关注瘙痒特异性结局的改善,但不宜预期总体生活质量短期显著提升。
局限性
- 纳入研究数量有限(5项RCT),总体样本量不大(n=660)。
- 总体健康相关生活质量结局证据确定性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Pruritus is a frequent and debilitating symptom in primary biliary cholangitis (PBC), substantially impairing sleep, mood and quality of life. Peroxisome proliferator-activated receptor (PPAR) agonists are promising second-line therapies for patients with an inadequate response to ursodeoxycholic acid (UDCA). We conducted a systematic review and meta-analysis to evaluate the efficacy of PPAR agonists on pruritus and health-related quality of life (HRQoL) in PBC. METHODS: We systematically searched for randomised placebo-controlled trials (RCTs) of PPAR agonists in PBC through December 2025. Eligible studies reported validated pruritus or HRQoL outcomes. Main outcomes were NRS and PBC-40 total score. Pooled estimates were calculated using random-effects models and expressed as mean differences (MD) with 95% confidence intervals (CI). RESULTS: Five RCTs evaluating bezafibrate, elafibranor and seladelpar (n = 660; 390 PPAR agonist; 270 placebo) met the inclusion criteria. For pruritus intensity analyses, data were restricted to participants with moderate-to-severe baseline symptoms (NRS ≥ 4) when available. PPAR agonists significantly reduced NRS scores at 3 months (MD, -1.39; 95% CI: -2.49 to -0.29), 6 months (MD, -1.17; 95% CI: -1.96 to -0.38) and 12 months (MD, -1.73; 95% CI, -3.00 to -0.46); in individual agent analyses, bezafibrate and seladelpar reached statistical significance at two or more time points. While improvements were also noted in PBC-40 itch-domain and 5D-itch score, an impact on overall HRQoL as reflected by PBC-40 total score could not be demonstrated, with a lower level of certainty. CONCLUSIONS: PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials.
引用
- Martins A, Khakoo NS, Corpechot C, et al. Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2026. PMID: 41869905. doi:10.1111/apt.70634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。